This chapter on prevention is set against a backdrop of high prevalence of hepatitis C among people who inject drugs. This high prevalence is primarily linked to the sharing of injection equipment, which poses a major risk for HCV transmission (Prithwish et al., 2008). Data from the literature indicate that these infections occur early in the course of injection drug use, likely as early as the first few injections and in a high-risk context. Several studies have indeed shown that recent injectors have higher rates of seroconversion for HIV and HCV than more experienced injection drug users (Nicolosi et al., 1992; van Ameijden et al., 1992; Garfein et al., 1998). Other sources indicate that young injection drug users engage in risky injection practices more frequently than older injection drug users (Thorpe et al., 2002; Des Jarlais et al., 2003). [Chapter excerpt]